Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
The New England Journal of Medicine (2014)
  • Richard R. Furman, Cornell University
  • Jeff P. Sharman, Cancer Institute
  • Steven E. Coutre, Stanford University
  • Bruce D. Cheson, Georgetown University
  • John M. Pagel, University of Washington
  • Peter Hillmen, St James's University Hospital
  • Jacqueline C. Barrientos, Hofstra University
  • Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center
  • Thomas J. Kipps, University of California, San Diego
  • Ian Flinn, Sarah Cannon Research Institute
  • Paolo Ghia, Vita-Salute San Raffaele University
  • Herbert Eradat, University of California, Los Angeles
  • Thomas Ervin, Harvard University
  • Nicole Lamanna, Columbia University
  • Bertrand Coiffier, Claude Bernard University Lyon 1
  • Andrew R. Pettitt, University of Liverpool
  • Shuo Ma, Northwestern University
  • Stephan Stilgenbauer, University of Ulm
  • Paula Cramer, University of Cologne
  • Maria Aiello
  • Dave M. Johnson
  • Langdon L. Miller, Pfizer
  • Daniel Li
  • Thomas M. Jahn, Children's Hospital Los Angeles
  • Roger D. Dansey, Wayne State University
  • Michael Hallek, University of Cologne
  • Susan M. O'Brien, University of Texas MD Anderson Cancer Center
Link
Disciplines
Publication Date
March 13, 2014
DOI
10.1056/NEJMoa1315226
Citation Information
Richard R. Furman, Jeff P. Sharman, Steven E. Coutre, Bruce D. Cheson, et al.. "Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia" The New England Journal of Medicine Vol. 370 Iss. 11 (2014) p. 997 - 1007
Available at: http://works.bepress.com/john-pagel/98/